C
Camilo E. Quevedo
Researcher at University of Oxford
Publications - 12
Citations - 469
Camilo E. Quevedo is an academic researcher from University of Oxford. The author has contributed to research in topics: Small molecule & Bicyclic molecule. The author has an hindex of 9, co-authored 12 publications receiving 361 citations. Previous affiliations of Camilo E. Quevedo include University of Birmingham & John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription
Kenneth Burnside Ramsay Ewan,Bożena Pajak,Mark Stubbs,Helen Todd,Olivier Barbeau,Camilo E. Quevedo,Hannah Botfield,Rodrigo M. Young,Ruth Ruddle,Lee Samuel,Alysia Battersby,Florence I. Raynaud,Nicholas D. Allen,Stephen W. Wilson,Branko V. Latinkić,Paul Workman,Edward McDonald,Julian Blagg,Wynne Aherne,Trevor Clive Dale +19 more
TL;DR: A practical approach to identify small-molecule inhibitors of Wnt signaling that can seed the development of agents suitable to treat patients with Wnt-dependent tumors is illustrated.
Journal ArticleDOI
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.
Camilo E. Quevedo,Abimael Cruz-Migoni,Abimael Cruz-Migoni,Nicolas Bery,Ami Miller,Tomoyuki Tanaka,Donna Petch,Carole J. R. Bataille,Lydia Y. W. Lee,Phillip S. Fallon,Hanna Tulmin,Hanna Tulmin,Matthias T. Ehebauer,Matthias T. Ehebauer,Narcis Fernandez-Fuentes,Narcis Fernandez-Fuentes,Angela J. Russell,Stephen B. Carr,Stephen B. Carr,Simon E. V. Phillips,Simon E. V. Phillips,Terence H. Rabbitts +21 more
TL;DR: Small molecules are identified that inhibit RAS-effector interactions and readily penetrate cells and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.
Journal ArticleDOI
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.
Abimael Cruz-Migoni,Peter Canning,Camilo E. Quevedo,Carole J. R. Bataille,Nicolas Bery,Ami Miller,Angela J. Russell,Simon E. V. Phillips,Stephen B. Carr,Terence H. Rabbitts +9 more
TL;DR: Fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series is created, and a set of compounds that inhibit RAS-effector interactions with increased potency are created.
Journal ArticleDOI
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.
Nicolas Bery,Abimael Cruz-Migoni,Abimael Cruz-Migoni,Carole J. R. Bataille,Camilo E. Quevedo,Hanna Tulmin,Ami Miller,Angela J. Russell,Simon E. V. Phillips,Stephen B. Carr,Stephen B. Carr,Terence H. Rabbitts +11 more
TL;DR: A robust set of bioluminescence resonance energy transfer (BRET)-based RAS biosensors that enable monitoring of RAS-effector interaction inhibition in living cells and represent a useful tool to investigate and characterize the potency of anti-RAS inhibitors in cells and more generally any RAS protein-protein interaction (PPI) in cells.
Journal ArticleDOI
Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family
Carole J. R. Bataille,Méabh B. Brennan,Simon Byrne,Stephen G. Davies,Matthew J. Durbin,Oleg Fedorov,Kilian Huber,Alan M. Jones,Stefan Knapp,Gu Liu,Anna Nadali,Camilo E. Quevedo,Angela J. Russell,Roderick G. Walker,Robert Westwood,Graham Michael Wynne +15 more
TL;DR: An excellent pan-PIM isoform inhibition profile was observed across the series, while optimized examples show good selectivity over other kinases, and provides a promising starting point for further development of this series as a new cancer therapy through PIM kinase inhibition.